{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:57:35Z","timestamp":1789232255236,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Multiple sclerosis (MS) patients are excluded from studies of immune checkpoint inhibitors (ICIs) due to concern for MS flare. This study aims to report the incidence of MS relapse, immune-related adverse events (irAEs), and cancer outcomes in MS patients with solid-organ malignancy treated with ICIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this retrospective study, MS patients who received ICIs at University Hospitals Seidman Cancer Center were identified electronically. Information on MS relapses, irAEs, and cancer outcomes after ICI initiation was collected and analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve patients were included in the study, all of whom had inactive MS. No patient experienced MS relapse or new lesions on brain MRI after ICI initiation. Two patients (16.7%) had severe irAEs (grade \u2265 3), which was acute pneumonitis. No deaths were associated. The objective response rate was 50%. An additional year of age was associated with a 14.2% decrease in the risk of developing severe irAEs (hazard ratio (HR) = 0.858; 95% confidence interval (CI): 0.798\u20130.922; P\u2005&amp;lt;\u2005.0001) and a 10.3% decrease in the risk of disease progression (HR = 0.897; 95% CI: 0.823\u20130.976; P\u2005=\u2005.0120). No significant difference in risk of having severe irAEs, overall survival, or progression-free survival was found between MS patients with and without DMTs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study suggests that ICIs could be safely used in patients with inactive MS with a low risk of MS relapse and comparable irAE risk with the general population. Although larger studies are needed for confirmation, the benefit of using ICIs to treat solid-organ malignancies might outweigh the risk of withholding treatment for this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf048","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:01:58Z","timestamp":1741140118000},"source":"Crossref","is-referenced-by-count":2,"title":["Outcomes in patients with multiple sclerosis and solid organ cancers treated with immune checkpoint inhibitors"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-9466","authenticated-orcid":false,"given":"Chanawee","family":"Hirunpattarasilp","sequence":"first","affiliation":[{"name":"Princess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy , Bangkok ,","place":["Thailand"]},{"name":"Department of Neurology, University Hospitals Cleveland Medical Center , Cleveland, Ohio ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-5218","authenticated-orcid":false,"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University , Cleveland, Ohio ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee Park","family":"Margevicius","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University , Cleveland, Ohio ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mirsky","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University Hospitals Seidman Cancer Center , Cleveland, Ohio ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Bruno","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,\u00a0City of Hope Atlanta , Newnan, Georgia ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Mangla","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University Hospitals Seidman Cancer Center , Cleveland, Ohio ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Stephen","family":"Hoehn","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center , Cleveland, Ohio ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke Daniel","family":"Rothermel","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center , Cleveland, Ohio ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Yeong-Fung","family":"Sheng","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University Hospitals Seidman Cancer Center , Cleveland, Ohio ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"issue":"8","key":"2025042206265681500_CIT0001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"issue":"11","key":"2025042206265681500_CIT0002","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"2025042206265681500_CIT0003","doi-asserted-by":"crossref","first-page":"1192762","DOI":"10.3389\/fmed.2023.1192762","article-title":"Immune checkpoint inhibitors efficacy across solid cancers and the utility of","volume":"10","author":"Fitzsimmons","year":"2023","journal-title":"Front Med"},{"issue":"4","key":"2025042206265681500_CIT0004","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"2025042206265681500_CIT0005","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2025042206265681500_CIT0006","doi-asserted-by":"crossref","first-page":"1756286418799864","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off\u2019 the immune system","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"2025042206265681500_CIT0007","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA."},{"issue":"12","key":"2025042206265681500_CIT0008","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat Rev Neurol."},{"issue":"10422","key":"2025042206265681500_CIT0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"2025042206265681500_CIT0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ene.15226","article-title":"Incidence and risk of cancer among multiple sclerosis patients: a matched population-based cohort study","volume":"29","author":"Bosco-L\u00e9vy","year":"2022","journal-title":"Eur J Neurol."},{"issue":"6","key":"2025042206265681500_CIT0011","first-page":"100183","article-title":"Intracranial complications from immune checkpoint therapy in a patient with NSCLC and multiple sclerosis: case report","volume":"2","author":"Lu","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"5","key":"2025042206265681500_CIT0012","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult Scler."},{"issue":"16","key":"2025042206265681500_CIT0013","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology."},{"issue":"3","key":"2025042206265681500_CIT0014","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/13524585221117949","article-title":"Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors","volume":"29","author":"Conway","year":"2023","journal-title":"Mult Scler."},{"issue":"10","key":"2025042206265681500_CIT0015","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol."},{"issue":"2","key":"2025042206265681500_CIT0016","doi-asserted-by":"crossref","first-page":"e200202","DOI":"10.1212\/NXI.0000000000200202","article-title":"Impact of immune checkpoint inhibitors on the course of multiple sclerosis","volume":"11","author":"Androdias","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"2025042206265681500_CIT0017","first-page":"20552173241252563","article-title":"Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis","volume":"10","author":"Nylander","year":"2024","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2025042206265681500_CIT0018","doi-asserted-by":"crossref","first-page":"112928","DOI":"10.1016\/j.ejca.2023.05.016","article-title":"Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis","volume":"189","author":"Chavaz","year":"2023","journal-title":"Eur J Cancer"},{"issue":"11","key":"2025042206265681500_CIT0019","doi-asserted-by":"crossref","first-page":"e210003","DOI":"10.1212\/WNL.0000000000210003","article-title":"Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications","volume":"103","author":"Quinn","year":"2024","journal-title":"Neurology."},{"issue":"1","key":"2025042206265681500_CIT0020","doi-asserted-by":"crossref","first-page":"e16547","DOI":"10.1111\/ene.16547","article-title":"Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis","volume":"32","author":"Gelibter","year":"2025","journal-title":"Eur J Neurol."},{"issue":"2","key":"2025042206265681500_CIT0021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"446","key":"2025042206265681500_CIT0022","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc."},{"issue":"282","key":"2025042206265681500_CIT0023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"issue":"2","key":"2025042206265681500_CIT0024","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B"},{"issue":"1","key":"2025042206265681500_CIT0025","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J"},{"issue":"1","key":"2025042206265681500_CIT0026","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun."},{"issue":"12","key":"2025042206265681500_CIT0027","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1177\/1352458519866613","article-title":"Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis","volume":"26","author":"Schwehr","year":"2020","journal-title":"Mult Scler."},{"issue":"5","key":"2025042206265681500_CIT0028","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult Scler."},{"issue":"10","key":"2025042206265681500_CIT0029","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology."},{"key":"2025042206265681500_CIT0030","author":"National Cancer Institute","year":"2021"},{"issue":"10","key":"2025042206265681500_CIT0031","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J Neurol."},{"key":"2025042206265681500_CIT0032","doi-asserted-by":"crossref","first-page":"824926","DOI":"10.3389\/fneur.2022.824926","article-title":"Therapeutic advances in multiple sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Neurol."},{"issue":"17","key":"2025042206265681500_CIT0033","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology."},{"key":"2025042206265681500_CIT0034","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol."},{"issue":"1","key":"2025042206265681500_CIT0035","doi-asserted-by":"crossref","first-page":"e6879","DOI":"10.1002\/cam4.6879","article-title":"Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer","volume":"13","author":"Rong","year":"2024","journal-title":"Cancer Med"},{"key":"2025042206265681500_CIT0036","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fonc.2020.01785","article-title":"Pneumonitis induced by immune checkpoint inhibitors: from clinical data to translational investigation","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol."},{"issue":"3","key":"2025042206265681500_CIT0037","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1753465816636557","article-title":"Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"10","author":"Abdel-Rahman","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"2025042206265681500_CIT0038","doi-asserted-by":"crossref","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol."},{"issue":"3","key":"2025042206265681500_CIT0039","doi-asserted-by":"crossref","first-page":"e001935","DOI":"10.1136\/jitc-2020-001935","article-title":"Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA","volume":"9","author":"Kalinich","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"11","key":"2025042206265681500_CIT0040","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cancers16112159","article-title":"Real-world prevalence and tolerability of immune-related adverse events in older adults with non-small cell lung cancer: a multi-institutional retrospective study","volume":"16","author":"Matsukane","year":"2024","journal-title":"Cancers"},{"issue":"12","key":"2025042206265681500_CIT0041","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"2025042206265681500_CIT0042","doi-asserted-by":"crossref","first-page":"e000871","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer."},{"issue":"1","key":"2025042206265681500_CIT0043","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"7","key":"2025042206265681500_CIT0044","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cllc.2023.05.006","article-title":"Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in non\u2013small-cell lung cancer","volume":"24","author":"Aung","year":"2023","journal-title":"Clin Lung Cancer."},{"key":"2025042206265681500_CIT0045","doi-asserted-by":"crossref","first-page":"625872","DOI":"10.3389\/fonc.2021.625872","article-title":"The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol."},{"issue":"5","key":"2025042206265681500_CIT0046","doi-asserted-by":"crossref","first-page":"100577","DOI":"10.1016\/j.esmoop.2022.100577","article-title":"The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression","volume":"7","author":"Kim","year":"2022","journal-title":"ESMO Open"},{"issue":"8","key":"2025042206265681500_CIT0047","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2217\/imt-2019-0124","article-title":"Efficacy of immune checkpoint inhibitors and age in cancer patients","volume":"12","author":"Huang","year":"2020","journal-title":"Immunotherapy"},{"issue":"3","key":"2025042206265681500_CIT0048","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jtho.2018.11.011","article-title":"Impact of age on outcomes with immunotherapy in patients with non\u2013small cell lung cancer","volume":"14","author":"Lichtenstein","year":"2019","journal-title":"J Thor Oncol"},{"issue":"4","key":"2025042206265681500_CIT0049","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies","volume":"50","author":"Talari","year":"2020","journal-title":"J R Coll Physicians Edinb."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf048\/62266267\/vdaf048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf048\/62266267\/vdaf048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf048\/62266267\/vdaf048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:27:09Z","timestamp":1745317629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf048\/8051845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf048","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf048"}}